SignalXSignalX

Enliven Therapeutics, Inc. (ELVN) 8-K Current Report — March 3, 2026

Filed: March 3, 2026
Health Care
Pharmaceutical Preparations
Enliven Therapeutics, Inc. Overview

Enliven Therapeutics, Inc. (ELVN) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

Enliven Therapeutics, Inc. 8-K Mar 3, 2026 Event Analysis

Item 2.02 · Results of Operations and Financial Condition

  • • Enliven Therapeutics (ELVN) reported Q4 and full-year 2025 financial results via press release dated March 3, 2026
  • • Full financial details in Exhibit 99.1 — press release contains key figures not reproduced in this filing item

Get deeper insights on Enliven Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.